In this paper based on studies from various groups, we explored issues in preventive nucleoside analog administration, including optimal administration period and the utility of concurrent use of these drugs. rituximab, reactivation of HBV was a major complication of chemotherapy-induced immunosuppression [820]. The events leading to HBV reactivation during rituximab/chemotherapy combination treatment have been reported by numerous groups, as have the effects of preventive administration of the nucleoside analogue lamivudine around the suppression of HBV reactivation [2133]. However, a number of issues remain to be decided, such as the level of HBV resistance to lamivudine, the optimal lamivudine administration period, and even whether or not lamivudine is the best preventive drug to use. HBV reactivation may result in a quantity of severe outcomes, including death from hepatitis [2337]. Additionally, even in the event that hepatitis is usually prevented, possible problems in subsequent lymphoma treatment or in anticipated outcomes may arise, such as lymphoma recurrence or shortened survival prognosis. In this paper based on studies from numerous groups, we explored issues in preventive nucleoside analog administration, including optimal administration period and the Calcifediol monohydrate power of concurrent use of these drugs. The discussion includes a compilation of our results on preventive administration of nucleoside analogs in HBs antigen- (HBsAg-) positive cases, which were accrued from your debut of rituximab in Japan in 2002 to December 2008. == 2. HBV Reactivation during Rituximab Administration == Acute hepatitis caused by HBV is usually in the beginning suppressed by cytokines secreted from NK and other types of cells. CD8-positive cells subsequently induce a CTL reaction which then eventually prospects to hepatitis. Since hepatitis is usually triggered by CTLs, a time lag exists from initial contamination to hepatitis onset [38,39]. However, hepatitis that arises from HBV reactivation, unlike that which occurs during standard HBV infection, is usually under a state of immunosuppression of the normal immunological responses to HBV, leading to increased viral replication and common contamination of hepatocytes. When immunosuppression is usually removed by discontinuation of chemotherapy, immune competence is usually restored and infected hepatocytes are rapidly damaged, leading to hepatitis. It is therefore likely that reactivated HBV results in a shorter time period to hepatitis progression than seen in standard HBV contamination. We believe that this mechanism of hepatitis aggravation can explain those case patients who pass away despite administration of lamivudine Rabbit Polyclonal to NFYC in response to HBV reactivation during chemotherapy or use of immunosuppressive drugs. In contrast, HCV tends to become chronic through suppression of the induction and amplification of immune responses (such as interferons) from your outset, and this may be why hepatitis caused by HCV reactivation during the use of anticancer or Calcifediol monohydrate immunosuppressive drugs is usually less likely to become severe [4042]. We have reported on reactivation of HBV and hepatitis during rituximab treatment alone or in combination with chemotherapy. Other groups have reported a rate of HBV reactivation of 20%~55% [15,1820]. One statement claims an HBV reactivation rate of 3%, even in HBsAg-negative cases [43]. Umemura et al. reported a 4% rate of HBV reactivation in HBsAg-positive patients based on a questionnaire conducted in Japan, which is lower than previous studies, and 20% of these patients developed fatal hepatitis [44]. Frequent HBV reactivation is also thought to occur as a complication of chemotherapy during treatment of lymphomas and may be influenced by steroids [18,45,46]. Since the initial use of rituximab in the medical center, debate has centered on whether rituximab alone can induce HBV reactivation or whether it does so only when used in combination with chemotherapy. In the beginning, we believed that rituximab alone was unlikely to induce HBV reactivation Calcifediol monohydrate [21]. However, Calcifediol monohydrate subsequent reports by us and by Yang et al. have shown that HBV reactivation can occur with rituximab alone, and it is therefore likely that rituximab itself can induce HBV reactivation [22,37]. Although reactivation of HBV is deemed more likely when rituximab is usually combined with chemotherapy.